abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

14 Feb 2007

Author:
[opinion] Philip Stevens, International Policy Network, in Nation [Thailand]

Licensing policy fatal for HIV/Aids sufferers [Thailand]

The government has just broken the patents on two more drugs [Kaletra by Abbott Laboratories, Plavix by Sanofi-Aventis & Bristol-Myers Squibb] and is on the verge of breaking 11 more, loudly applauded by international activists... It claims the only way to reconcile the need for expensive drugs with universal healthcare is by breaching patents and manufacturing the drugs oneself. But behind the rhetoric, the military government...show an inexplicable disregard for patients... Last August, the Global Fund...withdrew funding for [a Thai Govt-produced AIDS drug] because the [Govt. Pharmaceutical Organization] still had not brought its facilities up to standard... But it was too little too late: Thai scientists had announced back in July 2005 that the poor-quality GPO-Vir was causing a rise in patients' drug resistance. [also refers to Efavirenz (Bristol-Myers Squibb AIDS drug)]

Timeline